StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $19.40 | $20.26 | +4.43% | 1.0M |
| 05-12 | $19.88 | $19.11 | -3.87% | 0.5M |
| 05-13 | $18.84 | $18.96 | +0.64% | 0.7M |
| 05-14 | $18.98 | $18.68 | -1.58% | 0.5M |
| 05-15 | $18.46 | $18.15 | -1.68% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $4.21M | $123.67M | $120.89M | $108.12M |
Operating Income | $-50.03M | $-54.21M | $-4.49M | $28.48M |
Net Income | $-44.50M | $-38.60M | $7.51M | $-12.29M |
EPS (Diluted) | $-0.45 | $-0.46 | $0.09 | $0.42 |
Total Assets | $736.43M | $448.66M | $459.84M | $359.59M |
Total Liabilities | $214.51M | $215.60M | $214.00M | $91.51M |
Cash & Equivalents | $159.86M | $129.88M | $208.34M | $69.43M |
Free Cash Flow OCF − CapEx | $-39.24M | $-27.50M | $16.28M | $-83.49M |
Shares Outstanding | 84.32M | 65.54M | 61.79M | 61.72M |
No sell-side coverage available for GLUE.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for GLUE.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).